Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer
- 31 May 2012
- journal article
- research article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 7 (5), 799-807
- https://doi.org/10.1097/jto.0b013e318248240b
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Risk Factors for Tumor Recurrence in Patients With Early-Stage (Stage I and II) Non-small Cell Lung CancerChest, 2011
- The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewalNature Cell Biology, 2011
- Pathologic Lymph Node Staging Practice and Stage-Predicted Survival After Resection of Lung CancerThe Annals of Thoracic Surgery, 2011
- International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung AdenocarcinomaJournal of Thoracic Oncology, 2011
- TAZ is a novel oncogene in non-small cell lung cancerOncogene, 2011
- Sprouty1 is a critical regulatory switch of mesenchymal stem cell lineage allocationThe FASEB Journal, 2010
- The IASLC Lung Cancer Staging Project: Proposals Regarding the Relevance of TNM in the Pathologic Staging of Small Cell Lung Cancer in the Forthcoming (Seventh) Edition of the TNM Classification for Lung CancerJournal of Thoracic Oncology, 2009
- Estrogen Receptor, Progesterone Receptor, Human Epidermal Growth Factor Receptor 2 (HER2), and Epidermal Growth Factor Receptor Expression and Benefit From Lapatinib in a Randomized Trial of Paclitaxel With Lapatinib or Placebo As First-Line Treatment in HER2-Negative or Unknown Metastatic Breast CancerJournal of Clinical Oncology, 2009
- TAZ controls Smad nucleocytoplasmic shuttling and regulates human embryonic stem-cell self-renewalNature Cell Biology, 2008
- Treatment of Non-small Cell Lung Cancer Stage I and Stage IIChest, 2007